Targeting LOXL2 and Cardiac Fibrosis for Post-acute Heart Failure Treatment- A Prospective Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-100
SponsorChang Gung Memorial Hospital

About this trial

A previous study demonstrated that a multidisciplinary cardiac rehabilitation (CR) program was associated with reduced medium- to long-term all-cause mortality in a retrospective propensity score-matched study. The investigators will further investigate the predictors including LOXl2, cardiac MRI, and endothelial function that will benefit from a successful CR.

Eligibility criteria

Qualifiers

Patients must give written informed consent before any assessment is performed.

Inpatients >= 20 years of age, male or female.

Patients with a diagnosis of heart failure New York Heart Association (NYHA) class II-IV with BNP >=100 pg/mL or NT-porBNP >= 400 pg/mL ( >= 900 pg/mL if concomitant atrial fibrillation)

Left ventricular ejection fraction <= 40% by echocardiography or other methods

Disqualifiers

Estimated survival time < 6 months

Long-term bedridden for more than 3 months

Cannot tolerate exercise test due to muscular skeletal disorder.

Cannot cooperate all functional studies

Trial design

Treatments tested in this trial

  • exercise based cardiac rehabilitation

Treatment groups

130 Participants
are divided into 1 treatment group

Sponsors and collaborators